These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38725780)

  • 41. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021.
    Di Minno A; Spadarella G; Esposito S; Mathew P; Di Minno G; Mannucci PM
    Blood Rev; 2021 Nov; 50():100849. PubMed ID: 34024681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
    Nogami K
    Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY).
    Jiménez-Yuste V; Peyvandi F; Klamroth R; Castaman G; Shanmukhaiah C; Rangarajan S; García Chavez J; Martinez R; Kenet G; Alzahrani H; Robson S; Schmitt C; Kiialainen A; Meier O; Ozelo M
    Res Pract Thromb Haemost; 2022 Nov; 6(8):e12837. PubMed ID: 36397934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
    Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
    Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
    Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
    J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
    Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
    Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
    [No Abstract]   [Full Text] [Related]  

  • 48. Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations.
    Yada K; Nogami K
    J Blood Med; 2019; 10():171-181. PubMed ID: 31308776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A.
    Mannucci PM
    Expert Opin Investig Drugs; 2020 Mar; 29(3):303-309. PubMed ID: 31990229
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
    Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Kasai R; Yoneyama K; Yoshida H; Nogami K
    Blood Adv; 2017 Oct; 1(22):1891-1899. PubMed ID: 29296836
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis.
    Shimonishi N; Sasai K; Ogiwara K; Furukawa S; Nakajima Y; Mizumachi K; Yada K; Takeyama M; Shima M; Mizuno N; Nogami K
    Int J Hematol; 2023 Dec; 118(6):690-698. PubMed ID: 37803190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
    Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
    Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emicizumab for All Pediatric Patients with Severe Hemophilia A.
    Wieland I
    Hamostaseologie; 2022 Apr; 42(2):104-115. PubMed ID: 35488163
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting.
    Gourzoulidis G; Stefanou G; Economou M; Vakalopoulou S; Filippidis G; Soultatis G; Kontos D; Tzima S; Ntemousis F; Fassa A; Kourlaba G
    Clin Drug Investig; 2022 Jan; 42(1):75-85. PubMed ID: 34874542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients.
    Patil R; Shanmukhaiah C; Gogtay NJ; Pandey P; Patil K; Jijina F; Madkaikar M
    J Thromb Haemost; 2024 Apr; 22(4):1024-1030. PubMed ID: 38160726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.
    Peyvandi F; Mahlangu JN; Pipe SW; Hay CRM; Pierce GF; Kuebler P; Kruse-Jarres R; Shima M
    J Thromb Haemost; 2021 Jan; 19 Suppl 1(Suppl 1):32-41. PubMed ID: 33331041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
    Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.